Progress in metallocarboxypeptidases and their small molecular weight inhibitors

Biochimie

Volumn 92, Issue 11, 2010, Pages 1484-1500

  Fernández, Daniel ^a   Pallarès, Irantzu ^a   Vendrell, Josep ^a   Avilés, Francesc X ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Biologically active metabolites; Metallocarboxypeptidase; Plasma enzymes; Small molecular weight inhibitor

Indexed keywords

(2) 7 AMINO 2 ((HYDROXY (2 METHYL 1 (3 PHENYLPROPANAMIDO)PROPYL)PHOSPHORYL)METHYL)HEPTANOIC ACID; 2 (1H IMIDAZOL 4 YL) 3 PHENYLPROPANOIC ACID; 2 (2 GUANIDINOETHYLTHIO)SUCCINIC ACID; 2 (2 HYDROXY 5 NITROPHENYL) 3 PHENYLPROPANOIC ACID; 2 (3 GUANIDINOPHENYL) 3 MERCAPTOPROPANOIC ACID; 2 [3 (AMINOMETHYL)PHENYL] 3 HYDROXY 2 METHYL 1 [[(3 PHENYLPROPYL)SULFONYL]AMINOPROPYL]PHOSPHORYL PROPANOIC ACID; 2 BENZYL 2 HYDROXYSUCCINIC ACID; 2 BENZYL 3 MERCAPTOPROPANOIC ACID; 2 GUANIDINO 3 MERCAPTOPROPANOIC ACID; 3 (2 AMINOETHYLTHIO) 2 (3 ((3CYCLOHEXYL 1 OXO 1 (1,2,4) 1,7,7 TRIMETHYLBICYCLO[2 2 1]HEPTAN 2 YLAMINO)PROPAN 2 YL)UREIDO)PROPANOIC ACID; 3 (2 GUANIDINOETHYLTHIO) 2 MERCAPTOMETHYL)PROPANOIC ACID; 3 (6 AMINOPYRIDIN 3 YL) 2 (1 ((5 (5 CHLOROTHIOPHEN 2 YL)ISOXAZOL 3 YL)METHYL) 1H IMIDAZOL 4 YL)PROPANOIC ACID; 3 (6 AMINOPYRIDIN 3 YL) 2 (1 ISOPENTYL 1H IMIDAZOL 4 YL)PROPANOIC ACID; 3 (6 AMINOPYRIDIN 3 YL) 2 (MERCAPTOMETHYL)PROPANOIC ACID; 5 AMINO 2 ((1PROPYL 1H IMIDAZOL 4 YL)METHYL)PENTANOIC ACID; 5 GUANIDINE 2 (MERCAPTOMETHYL)PENTANOIC ACID; AMINOPYRIDINE; AMINOPYRIDINE IMIDAZOLE ACID; ANABAENOPEPTIN G; BENZYLSUCCINIC ACID; CAPTOPRIL; CARBOXYPEPTIDASE; CIMICIFUGIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METALLOCARBOXYPEPTIDASE; N (HYDROXYAMINOCARBONYL)PHENYLALANINE; OCHRATOXIN; THUJAPLICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SUBSTRATE; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PANCREAS; PLASMA; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; CARBOXYPEPTIDASES; DRUG DESIGN; HUMANS; MOLECULAR WEIGHT; PROTEASE INHIBITORS;

ANIMALIA;

EID: 78149358940     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.05.002     Document Type: Review

References (248)

1. Rawlings N.D., Barrett A.J., Bateman A. MEROPS: the peptidase database. Nucleic Acids Res. 2009, 38:5.
2. Lipscomb W.N., Hartsuck J.A., Quiocho F.A., Reeke G.N. The structure of carboxypeptidase A. IX. The x-ray diffraction results in the light of the chemical sequence. Proc. Natl. Acad. Sci. USA 1969, 64:28-35.
3. Liebman M.N., Venanzi C.A., Weinstein H. Structural analysis of carboxypeptidase A and its complexes with inhibitors as a basis for modeling enzyme recognition and specificity. Biopolymers 1985, 24:1721-1758.
4. Firth-Clark S., Kirton S.B., Willems H.M., Williams A. De novo ligand design to partially flexible active sites: application of the ReFlex algorithm to carboxypeptidase A, acetylcholinesterase, and the estrogen receptor. J. Chem. Inf. Model. 2008, 48:296-305.
5. Raha K., Merz K.M. A quantum mechanics-based scoring function: study of zinc ion-mediated ligand binding. J. Am. Chem. Soc. 2004, 126:1020-1021.
6. Coll M., Guasch A., Aviles F.X., Huber R. Three-dimensional structure of porcine procarboxypeptidase B: a structural basis of its inactivity. EMBO J. 1991, 10:1-9.
7. Fernandez D., Boix E., Pallares I., Aviles F.X., Vendrell J. Analysis of a new crystal form of procarboxypeptidase B: further insights into the catalytic mechanism. Biopolymers 2010, 93:178-185.
8. Marx P.F., Brondijk T.H., Plug T., Romijn R.A., Hemrika W., Meijers J.C., Huizinga E.G. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Blood 2008, 112:2803-2809.
9. Hass G.M., Plikaytis B., Neurath H. Modification of the acetyl and nitro derivatives of carboxypeptidase A by N-bromoacetyl-N-methyl-L-phenylalanine. FEBS Lett. 1974, 46:162-165.
10. Johansen J.T., Klyosov A.A., Vallee B.L. Circular dichroism-inhibitor titrations of arsanilazotyrosine-248 carboxypeptidase A. Biochemistry 1976, 15:296-303.
11. Mock W.L., Chen J.T. The pH dependence of peptide hydrolysis by nitrocarboxypeptidase A. Arch. Biochem. Biophys. 1980, 203:542-552.
12. Petra P.H., Neurath H. Modification of carboxyl groups in bovine carboxypeptidase A. II. Chemical identification of a functional glutamic acid residue and other reactive groups. Biochemistry (Mosc) 1971, 10:3171-3177.
13. Lee S., Hwang B.K., Myoung Y.C., Suh J. Carboxypeptidase A-catalyzed hydrolysis of O-(alpha -acylamino-2-styrylacryloyl)-l-beta -phenyllactates: search of specific ester substrates hydrolyzed through accumulation of intermediates. Bioorg. Chem. 1995, 23:183-192.
14. Osumi A., Rahmo A., King S.W., Przystas T.J., Fife T.H. Substituent effects in the carboxypeptidase A catalyzed hydrolysis of substituted L, beta-phenyllactate esters. Biochemistry 1994, 33:14750-14757.
15. Auld D.S., Galdes A., Geoghegan K.F., Holmquist B., Martinelli R.A., Vallee B.L. Cryospectrokinetic characterization of intermediates in biochemical reactions: carboxypeptidase A. Proc. Natl. Acad. Sci. USA 1984, 81:5041-5045.
16. Kuo L.C., Makinen M.W. Hydrolysis of esters by carboxypeptidase A requires a penta-coordinate metal ion. J. Biol. Chem. 1982, 257:24-27.
17. Lee H.C., Ko Y.H., Baek S.B., Kim D.H. Detection of an anhydride intermediate in the carboxypeptidase A catalyzed hydrolysis of a peptide substrate by solid state NMR spectroscopy and its mechanistic implication. Bioorg. Med. Chem. Lett. 1998, 8:3379-3384.
18. Zhang H., Bryant R.G. Characterization of enzyme-bound ligand dynamics by solid-state NMR in the presence of ligand exchange: l-phenylalanine on carboxypeptidase A. Biophys. J. 1995, 68:303-311.
19. Zhang K., Dong J., Auld D.S. A time-resolved study of substrate hydrolysis of carboxypeptidase A. Physica B: Condensed Matter 1995, 208-209:719-721.
20. Liu Y.H., Konermann L. Enzyme conformational dynamics during catalysis and in the 'resting state' monitored by hydrogen/deuterium exchange mass spectrometry. FEBS Lett. 2006, 580:5137-5142.
21. Banci L., Bertini I., La Penna G. The enzymatic mechanism of carboxypeptidase: a molecular dynamics study. Proteins 1994, 18:186-197.
22. Banci L., Schroder S., Kollman P.A. Molecular dynamics characterization of the active cavity of carboxypeptidase A and some of its inhibitor adducts. Proteins 1992, 13:288-305.
23. Makinen M.W., Troyer J.M., van der Werff H., Berendsen H.J., van Gunsteren W.F. Dynamical structure of carboxypeptidase A. J. Mol. Biol. 1989, 207:201-216.
24. Alvarez-Santos S., Gonzalez-Lafont A., Lluch J.M., Oliva B., Aviles F.X. Theoretical study of the role of arginine 127 in the water-promoted mechanism of peptide cleavage by carboxypeptidase A. New J. Chem. 1998, 22:319-325.
25. Nakagawa S., Umeyama H. Ab initio molecular orbital study on the effects of zinc ion, its ligands and ionic amino acid residues for proton transfer energetics between Glu 270 and Zn co-ordinated water molecule in carboxypeptidase A. J. Theor. Biol. 1982, 96:473-493.
26. Scheiner S., Lipscomb W.N. Molecular orbital studies of enzyme activity. 4. Hydrolysis of peptides by carboxypeptidase A. J. Am. Chem. Soc. 1977, 99:3466-3472.
27. Szeto M.W.Y., Mujika J.I., Zurek J., Mulholland A.J., Harvey J.N. QM/MM study on the mechanism of peptide hydrolysis by carboxypeptidase A. THEOCHEM 2009, 898:106-114.
28. Xu D.G., Guo H. Quantum mechanical/molecular mechanical and density functional theory studies of a prototypical zinc peptidase (Carboxypeptidase A) suggest a general acid-general base mechanism. J. Am. Chem. Soc. 2009, 131:9780-9788.
29. Feinberg H., Greenblatt H.M., Behar V., Gilon C., Cohen S., Bino A., Shoham G. Zinc-directed inhibitors for zinc proteinases. Acta Crystallogr. D Biol. Crystallogr. 1995, 51:428-449.
30. Kim D.H., Lee S.S. Origin of rate-acceleration in ester hydrolysis with metalloprotease mimics. Bioorg. Med. Chem. 2000, 8:647-652.
31. Riordan J.F., Livingston D.M. Conformational and activity changes on subtilisin cleavage of carboxypeptidase A. Biochem. Biophys. Res. Commun. 1971, 44:695-701.
32. Cho J.H., Kim D.H., Lee K.J., Choi K.Y. The role of Tyr248 probed by mutant bovine carboxypeptidase A: insight into the catalytic mechanism of carboxypeptidase A. Biochemistry 2001, 40:10197-10203.
33. Gardell S.J., Craik C.S., Hilvert D., Urdea M.S., Rutter W.J. Site-directed mutagenesis shows that tyrosine 248 of carboxypeptidase A does not play a crucial role in catalysis. Nature 1985, 317:551-555.
34. Grishin A.M., Akparov V., Chestukhina G.G. Structural principles of the broad substrate specificity of Thermoactinomyces vulgaris carboxypeptidase T-role of amino acid residues at positions 260 and 262. Protein Eng. Des. Sel. 2008, 21:545-551.
35. Phillips M.A., Fletterick R., Rutter W.J. Arginine 127 stabilizes the transition state in carboxypeptidase. J. Biol. Chem. 1990, 265:20692-20698.
36. Schmuck C. How to improve guanidinium cations for oxoanion binding in aqueous solution?. Coord. Chem. Rev. 2006, 250:3053-3067.
37. Christianson D.W., Lipscomb W.N. Carboxypeptidase A. Acc. Chem. Res. 1989, 22:62-69.
38. Jensen F., Bukrinsky T., Bjerrum J., Larsen S. Three high-resolution crystal structures of cadmium-substituted carboxypeptidase A provide insight into the enzymatic function. J. Biol. Inorg. Chem. 2002, 7:490-499.
39. Kim D.H. Chemistry-based design of inhibitors for carboxypeptidase A. Curr. Top. Med. Chem. 2004, 4:1217-1226.
40. Lipscomb W.N., Strater N. Recent advances in zinc enzymology. Chem. Rev. 1996, 96:2375-2434.
41. Folk J.E. A new pancreatic carboxypeptidase. J. Am. Chem. Soc. 1956, 78:3541-3542.
42. Gladner J.A., Folk J.E., Carboxypeptidase B. Mode of action on protein substrates and its application to carboxyl terminal group analysis. J. Biol. Chem. 1958, 231:393-401.
43. Marinkovic D.V., Marinkovic J.N., Erdos E.G., Robinson C.J. Purification of carboxypeptidase B from human pancreas. Biochem. J. 1977, 163:253-260.
44. Wintersberger E., Cox D.J., Neurath H. Bovine pancreatic procarboxypeptidase B.I. Isolation, properties, and activation. Biochemistry 1962, 1:1069-1078.
45. Berger J., Schneeman B.O. Stimulation of bile-pancreatic zinc, protein and carboxypeptidase secretion in response to various proteins in the rat. J. Nutr. 1986, 116:265-272.
46. Friedman M., Grosjean O.K., Zahnley J.C. Inactivation of metalloenzymes by food constituents. Food Chem. Toxicol. 1986, 24:897-902.
47. Martinez-Montemayor M.M., Hill G.M., Raney N.E., Rilington V.D., Tempelman R.J., Link J.E., Wilkinson C.P., Ramos A.M., Ernst C.W. Gene expression profiling in hepatic tissue of newly weaned pigs fed pharmacological zinc and phytase supplemented diets. BMC Genomics 2008, 9:421.
48. Parellada J., Suarez G., Guinea M. Inhibition of zinc metallopeptidases by flavonoids and related phenolic compounds: structure-activity relationships. J. Enzym. Inhib. 1998, 13:347-359.
49. Appelros S., Thim L., Borgström A. Activation peptide of carboxypeptidase B in serum and urine in acute pancreatitis. Gut 1998, 42:97-102.
50. Hilal M.A., Ung C.T., Westlake S., Johnson C.D. Carboxypeptidase-B activation peptide, a marker of pancreatic acinar injury, but not l-selectin, a marker of neutrophil activation, predicts severity of acute pancreatitis. J. Gastroenterol. Hepatol. 2007, 22:349-354.
51. Matsugi S., Hamada T., Shioi N., Tanaka T., Kumada T., Satomura S. Serum carboxypeptidase A activity as a biomarker for early-stage pancreatic carcinoma. Clin. Chim. Acta 2007, 378:147-153.
52. Vovchuk I.L., Petrov S.A. Role of carboxypeptidases in carcinogenesis. Biomed. Khim. 2008, 54:167-178.
53. Goldstein S.M., Kaempfer C.E., Kealey J.T., Wintroub B.U. Human mast cell carboxypeptidase. Purification and characterization. J. Clin. Invest. 1989, 83:1630-1636.
54. Serafin W.E., Dayton E.T., Gravallese P.M., Austen K.F., Stevens R.L. Carboxypeptidase A in mouse mast cells. Identification, characterization, and use as a differentiation marker. J. Immunol. 1987, 139:3771-3776.
55. Feyerabend T.B., Hausser H., Tietz A., Blum C., Hellman L., Straus A.H., Takahashi H.K., Morgan E.S., Dvorak A.M., Fehling H.J., Rodewald H.R. Loss of histochemical identity in mast cells lacking carboxypeptidase A. Mol. Cell. Biol. 2005, 25:6199-6210.
56. Huang H., Reed C.P., Zhang J.S., Shridhar V., Wang L., Smith D.I. Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res. 1999, 59:2981-2988.
57. Ross P.L., Cheng I., Liu X., Cicek M.S., Carroll P.R., Casey G., Witte J.S. Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer 2009, 9:69.
58. Jin M., Ishida M., Katoh-Fukui Y., Tsuchiya R., Higashinakagawa T., Ikegami S., Arimatsu Y. Reduced pain sensitivity in mice lacking latexin, an inhibitor of metallocarboxypeptidases. Brain Res. 2006, 1075:117-121.
59. Pallarès I., Bonet R., García-Castellanos R., Ventura S., Avilés F.X., Vendrell J., Gomis-Rüth F.X. Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin. Proc. Natl. Acad. Sci. USA 2005, 102:3978-3983.
60. Lyons P.J., Callaway M.B., Fricker L.D. Characterization of carboxypeptidase A6, an extracellular matrix peptidase. J. Biol. Chem. 2008, 283:7054-7063.
61. Fialka F., Gruber R.M., Hitt R., Opitz L., Brunner E., Schliephake H., Kramer F.J. CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma-a pilot study. Oral Oncol. 2008, 44:941-948.
62. Kalinina E., Varlamov O., Fricker L.D. Analysis of the carboxypeptidase D cytoplasmic domain: implications in intracellular trafficking. J. Cell. Biochem. 2002, 85:101-111.
63. Song L., Fricker L.D. Purification and characterization of carboxypeptidase D, a novel carboxypeptidase E-like enzyme, from bovine pituitary. J. Biol. Chem. 1995, 270:25007-25013.
64. Hadkar V., Skidgel R.A. Carboxypeptidase D is up-regulated in raw 264.7 macrophages and stimulates nitric oxide synthesis by cells in arginine-free medium. Mol. Pharmacol. 2001, 59:1324-1332.
65. Hadkar V., Sangsree S., Vogel S.M., Brovkovych V., Skidgel R.A. Carboxypeptidase-Mediated enhancement of nitric oxide production in rat lungs and microvascular endothelial cells, Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287:35-45.
66. Abdelmagid S.A., Too C.K. Prolactin and estrogen up-regulate carboxypeptidase-d to promote nitric oxide production and survival of mcf-7 breast cancer cells. Endocrinology 2008, 149:4821-4828.
67. Hoff N.P., Degrandi D., Hengge U., Pfeffer K., Wurthner J.U. Carboxypeptidase D: a novel TGF-beta target gene dysregulated in patients with lupus erythematosus. J. Clin. Immunol. 2007, 27:568-579.
68. Fricker L.D., Snyder S.H. Purification and characterization of enkephalin convertase, an enkephalin-synthesizing carboxypeptidase. J. Biol. Chem. 1983, 258:10950-10955.
69. Rindler M.J. Carboxypeptidase E, a peripheral membrane protein implicated in the targeting of hormones to secretory granules, co-aggregates with granule content proteins at acidic pH. J. Biol. Chem. 1998, 273:31180-31185.
70. Cool D.R., Normant E., Shen F., Chen H.C., Pannell L., Zhang Y., Loh Y.P. Carboxypeptidase E is a regulated secretory pathway sorting receptor: genetic obliteration leads to endocrine disorders in Cpe(fat) mice. Cell 1997, 88:73-83.
71. Hosaka M., Watanabe T., Sakai Y., Kato T., Takeuchi T. Interaction between secretogranin III and carboxypeptidase E facilitates prohormone sorting within secretory granules. J. Cell Sci. 2005, 118:4785-4795.
72. A. Woronowicz, N.X. Cawley, S.Y. Chang, H. Koshimizu, A.W. Phillips, Z.G. Xiong, Y.P. Loh, Carboxypeptidase E knockout mice exhibit abnormal dendritic arborization and spine morphology in central nervous system neurons, J. Neurosci. Res. 88 (2010) 64-72.
73. Jeffrey K.D., Alejandro E.U., Luciani D.S., Kalynyak T.B., Hu X., Li H., Lin Y., Townsend R.R., Polonsky K.S., Johnson J.D. Carboxypeptidase E mediates palmitate-induced beta-cell ER stress and apoptosis. Proc. Natl. Acad. Sci. USA 2008, 105:8452-8457.
74. Koshimizu H., Senatorov V., Loh Y.P., Gozes I. Neuroprotective protein and carboxypeptidase E. J. Mol. Neurosci. 2009, 39:1-8.
75. Ramis J.M., Franssen-van Hal N.L., Kramer E., Llado I., Bouillaud F., Palou A., Keijer J. Carboxypeptidase E and thrombospondin-1 are differently expressed in subcutaneous and visceral fat of obese subjects. Cell. Mol. Life Sci. 2002, 59:1960-1971.
76. Solov'ev V.B., Gengin M.T. Effect of arecholine and atropine administration on the carboxypeptidase H and phenylmethylsulfonyl fluoride-inhibited carboxypeptidase activities in the rat nervous tissue. Biomed. Khim. 2008, 54:201-209.
77. Zhang X., Zhu J., Loh Y.P., Berghman L.R. Carboxypeptidase E, an essential element of the regulated secretory pathway, is expressed and partially co-localized with chromogranin A in chicken thymus. Cell Tissue Res. 2009, 337:371-379.
78. Skidgel R.A., Deddish P.A., Davis R.M. Isolation and characterization of a basic carboxypeptidase from human seminal plasma. Arch. Biochem. Biophys. 1988, 267:660-667.
79. McGwire G.B., Skidgel R.A. Extracellular conversion of epidermal growth factor (EGF) to des-Arg53-EGF by carboxypeptidase M. J. Biol. Chem. 1995, 270:17154-17158.
80. Nishioka Y., Higuchi T., Sato Y., Yoshioka S., Tatsumi K., Fujiwara H., Fujii S. Human migrating extravillous trophoblasts express a cell surface peptidase, carboxypeptidase-M. Mol. Hum. Reprod. 2003, 9:799-806.
81. Tsakiris I., Soos G., Nemes Z., Kiss S.S., Andras C., Szanto J., Dezso B. The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas: the coexistence predicts a poor prognosis regardless of EGFR levels. J. Cancer Res. Clin. Oncol. 2008, 134:439-451.
82. Reznik S.E., Fricker L.D. Carboxypeptidases from A to Z: implications in embryonic development and Wnt binding. Cell. Mol. Life Sci. 2001, 58:1790-1804.
83. Moeller C., Swindell E.C., Kispert A., Eichele G. Carboxypeptidase Z (CPZ) modulates Wnt signaling and regulates the development of skeletal elements in the chicken. Development 2003, 130:5103-5111.
84. Matsumoto A., Itoh K., Matsumoto R. A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus. Eur. J. Neurosci. 2000, 12:227-238.
85. Rodriguez de la Vega M., Sevilla R.G., Hermoso A., Lorenzo J., Tanco S., Diez A., Fricker L.D., Bautista J.M., Aviles F.X. Nna1-like proteins are active metallocarboxypeptidases of a new and diverse M14 subfamily. FASEB J. 2007, 21:851-865.
86. Erdos E.G., Sloane E.M. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol. 1962, 11:585-592.
87. Quagraine M.O., Tan F., Tamei H., Erdos E.G., Skidgel R.A. Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N. Biochem. J. 2005, 388:81-91.
88. Mathews K.P., Pan P.M., Amendola M.A., Lewis F.H. Plasma protease inhibitor and anaphylatoxin inactivator levels in chronic urticaria/angioedema and in patients experiencing anaphylactoid reactions to radiographic contrast media. Int. Arch. Allergy Appl. Immunol. 1986, 79:220-223.
89. Cao H., Hegele R.A. DNA polymorphism and mutations in CPN1, including the genomic basis of carboxypeptidase N deficiency. J. Hum. Genet. 2003, 48:20-22.
90. Willemse J.L., Chen D., Hendriks D.F. Major carboxypeptidase N deficiency. Clin. Chim. Acta 2008, 389:181-182.
91. Mueller-Ortiz S.L., Wang D., Morales J.E., Li L., Chang J.Y., Wetsel R.A. Targeted disruption of the gene encoding the murine small subunit of carboxypeptidase N (CPN1) causes susceptibility to C5a anaphylatoxin-mediated shock. J. Immunol. 2009, 182:6533-6539.
92. Hendriks D., Scharpe S., van Sande M., Lommaert M.P. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J. Clin. Chem. Clin. Biochem. 1989, 27:277-285.
93. Eaton D.L., Malloy B.E., Tsai S.P., Henzel W., Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 1991, 266:21833-21838.
94. Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 1995, 270:14477-14484.
95. Campbell W., Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem. Biophys. Res. Commun. 1989, 162:933-939.
96. Valnickova Z., Christensen T., Skottrup P., Thogersen I.B., Hojrup P., Enghild J.J. Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation. Biochemistry 2006, 45:1525-1535.
97. Boffa M.B., Wang W., Bajzar L., Nesheim M.E. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J. Biol. Chem. 1998, 273:2127-2135.
98. Valnickova Z., Thogersen I.B., Potempa J., Enghild J.J. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. J. Biol. Chem. 2007, 282:3066-3076.
99. Keil C., Maskos K., Than M., Hoopes J.T., Huber R., Tan F., Deddish P.A., Erdos E.G., Skidgel R.A., Bode W. Crystal structure of the human carboxypeptidase N (kininase I) catalytic domain. J. Mol. Biol. 2007, 366:504-516.
100. Anand K., Pallares I., Valnickova Z., Christensen T., Vendrell J., Wendt K.U., Schreuder H.A., Enghild J.J., Aviles F.X. The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa. J. Biol. Chem. 2008, 283:29416-29423.
101. Valnickova Z., Thaysen-Andersen M., Hojrup P., Christensen T., Sanggaard K.W., Kristensen T., Enghild J.J. Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI). BMC Biochem. 2009, 10:13.
102. Ceresa E., Van de Borne K., Peeters M., Lijnen H.R., Declerck P.J., Gils A. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. J. Biol. Chem. 2006, 281:15878-15883.
103. Knecht W., Willemse J., Stenhamre H., Andersson M., Berntsson P., Furebring C., Harrysson A., Hager A.C., Wissing B.M., Hendriks D., Cronet P. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis. FEBS J. 2006, 273:778-792.
104. Sanglas L., Valnickova Z., Arolas J.L., Pallares I., Guevara T., Sola M., Kristensen T., Enghild J.J., Aviles F.X., Gomis-Ruth F.X. Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis. Mol. Cell 2008, 31:598-606.
105. Boffa M.B., Bell R., Stevens W.K., Nesheim M.E. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 2000, 275:12868-12878.
106. Marx P.F., Hackeng T.M., Dawson P.E., Griffin J.H., Meijers J.C., Bouma B.N. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J. Biol. Chem. 2000, 275:12410-12415.
107. Marx P.F., Plug T., Havik S.R., Morgelin M., Meijers J.C. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?. J. Thromb. Haemost. 2009, 7:445-452.
108. Byers L.D., Wolfenden R. A potent reversible inhibitor of carboxypeptidase A. J. Biol. Chem. 1972, 247:606-608.
109. Byers L.D., Wolfenden R. Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A. Biochemistry 1973, 12:2070-2078.
110. Fricker L.D., Plummer T.H., Snyder S.H. Enkephalin convertase: potent, selective, and irreversible inhibitors. Biochem. Biophys. Res. Commun. 1983, 111:994-1000.
111. Mao S.S., Colussi D., Bailey C.M., Bosserman M., Burlein C., Gardell S.J., Carroll S.S. Electrochemiluminescence assay for basic carboxypeptidases: inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor. Anal. Biochem. 2003, 319:159-170.
112. McKay T.J., Plummer T.H. By-product analogues for bovine carboxypeptidase B. Biochemistry 1978, 17:401-405.
113. Galardy R.E., Kortylewicz Z.P. Alpha-bromo ketone substrate analogues are powerful reversible inhibitors of carboxypeptidase A. Biochemistry 1985, 24:7607-7612.
114. Galardy R.E., Kortylewicz Z.P. Inhibition of carboxypeptidase A by aldehyde and ketone substrate analogues. Biochemistry 1984, 23:2083-2087.
115. Grobelny D., Goli U.B., Galardy R.E. 3-Phosphonopropionic acids inhibit carboxypeptidase A as multisubstrate analogues or transition-state analogues. Biochem. J. 1985, 232:15-19.
116. Wang S.H., Wang S.F., Xuan W., Zeng Z.H., Jin J.Y., Ma J., Tian G.R. Nitro as a novel zinc-binding group in the inhibition of carboxypeptidase A. Bioorg. Med. Chem. 2008, 16:3596-3601.
117. Kim D.H., Kim K.R. Beta-lactam derivatives as inhibitors for carboxypeptidase A. Enzyme inhibitor design 17. Bull. Kor. Chem. Soc. 1996, 17:34-38.
118. Cushman D.W., Ondetti M.A. Design of angiotensin converting enzyme inhibitors. Nat. Med. 1999, 5:1110-1113.
119. Cushman D.W., Cheung H.S., Sabo E.F., Ondetti M.A. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977, 16:5484-5491.
120. Ondetti M.A., Condon M.E., Reid J., Sabo E.F., Cheung H.S., Cushman D.W. Design of potent and specific inhibitors of carboxypeptidases A and B. Biochemistry 1979, 18:1427-1430.
121. Holmquist B., Vallee B.L. Metal-coordinating substrate analogs as inhibitors of metalloenzymes. Proc. Natl. Acad. Sci. USA 1979, 76:6216-6220.
122. Kim D.H., Shin Y.S., Kim K.B. The structural feature of S1' subsite of Carboxypeptidase-A. Bioorg. Med. Chem. Lett. 1991, 1:317-322.
123. Lee H.S., Kim D.H. Synthesis and evaluation of alpha, alpha-disubstituted-3-mercaptopropanoic acids as inhibitors for carboxypeptidase A and implications with respect to enzyme inhibitor design. Bioorg. Med. Chem. 2003, 11:4685-4691.
124. Lee M., Kim D.H. Syntheses and kinetic evaluation of racemic and optically active 2- benzyl-2-methyl-3,4-epoxybutanoic acids as irreversible inactivators for carboxypeptidase A. Bioorg. Med. Chem. 2002, 10:913-922.
125. Plummer T.H., Ryan T.J. A potent mercapto bi-product analogue inhibitor for human carboxypeptidase N. Biochem. Biophys. Res. Commun. 1981, 98:448-454.
126. Do Y.H., Gifford-Moore D.S., Beight D.W., Rathnachalam R., Klimkowski V.J., Warshawsky A.M., Lu D. Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives. Thromb. Res. 2005, 116:265-271.
127. Fisher G.H., Ryan J.W., Chung A., Plumer T.H. Synthetic inhibitors of carboxypeptidase N. Adv. Exp. Med. Biol. 1986, 198(Pt A):405-410.
128. Adler M., Bryant J., Buckman B., Islam I., Larsen B., Finster S., Kent L., May K., Mohan R., Yuan S., Whitlow M. Crystal structures of potent thiol-based inhibitors bound to carboxypeptidase B. Biochemistry 2005, 44:9339-9347.
129. Islam I., Bryant J., May K., Mohan R., Yuan S., Kent L., Morser J., Zhao L., Vergona R., White K., Adler M., Whitlow M., Buckman B.O. 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg. Med. Chem. Lett. 2007, 17:1349-1354.
130. M. Linschoten, M. Polla, Potential inhibitors of carboxypeptidase U, PCT Int. Appl. (Astrazeneca Ab, Swed.). WO 2000 066550, 62 pp.
131. Polla M.O., Tottie L., Norden C., Linschoten M., Musil D., Trumpp-Kallmeyer S., Aukrust I.R., Ringom R., Holm K.H., Neset S.M., Sandberg M., Thurmond J., Yu P., Hategan G., Anderson H. Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa). Bioorg. Med. Chem. 2004, 12:1151-1175.
132. M. Polla, Preparation of 2,5-disubstituted 3-mercaptopentanoic acids as carboxypeptidase U inhibitors, PCT Int. Appl. (Astrazeneca A.B., Swed.). WO 2003 106420, 38 pp.
133. Lee K.J., Joo K.C., Kim E.J., Lee M., Kim D.H. A new type of carboxypeptidase A inhibitors designed using an imidazole as a zinc coordinating ligand. Bioorg. Med. Chem. 1997, 5:1989-1998.
134. Barrow J.C., Nantermet P.G., Stauffer S.R., Ngo P.L., Steinbeiser M.A., Mao S.S., Carroll S.S., Bailey C., Colussi D., Bosserman M., Burlein C., Cook J.J., Sitko G., Tiller P.R., Miller-Stein C.M., Rose M., McMasters D.R., Vacca J.P., Selnick H.G. Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J. Med. Chem. 2003, 46:5294-5297.
135. Nantermet P.G., Barrow J.C., Lindsley S.R., Young M., Mao S.S., Carroll S., Bailey C., Bosserman M., Colussi D., McMasters D.R., Vacca J.P., Selnick H.G. Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg. Med. Chem. Lett. 2004, 14:2141-2145.
136. C. Kallus, H. Heitsch, A. Lindenschmidt, S. Grueneberg, Preparation of imidazoleacetic acids and related compounds as TAFLa inhibitors, (Aventis Pharma Deutschland GmbH, Germany). Appl. WO 2005 105781, 127 pp.
137. C.M.N. Allerton, J. Blagg, M.E. Bunnage, J. Steele, Preparation of substituted imidazoles as TAFIa inhibitors, PCT Int. Appl. (Pfizer Limited, UK; Pfizer Inc.). WO 2002 014285, 183 pp.
138. C.M.N. Allerton, D.J. Bull, M.E. Bunnage, R.J. Maguire, J. Steele, Preparation of 3-(imidazolyl)-2-alkoxypropanoic acids as selective TAFIa inhibitors for treating thrombotic and other conditions associated with fibrin deposition, PCT Int. Appl. (Pfizer Limited, UK; Pfizer Inc.). WO 2003 061652, 153 pp.
139. Bunnage M.E., Blagg J., Steele J., Owen D.R., Allerton C., McElroy A.B., Miller D., Ringer T., Butcher K., Beaumont K., Evans K., Gray A.J., Holland S.J., Feeder N., Moore R.S., Brown D.G. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J. Med. Chem. 2007, 50:6095-6103.
140. Mock W.L., Freeman D.J., Aksamawati M. Fluxionate Lewis acidity of the Zn2+ ion in carboxypeptidase A. Biochem. J. 1993, 289(Pt 1):185-193.
141. Chung S.J., Kim D.H. N-(Hydroxyaminocarbonyl)phenylalanine: a novel class of inhibitor for carboxypeptidase A. Bioorg. Med. Chem. 2001, 9:185-189.
142. C. Kallus, M. Broenstrup, W. Czechtizky, A. Evers, M. Follmann, N. Halland, H. Schreuder, Urea and sulfamide derivatives as TAFIA inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases, (Sanofi-Aventis, Fr.). Appl. WO 2008 067909, 190pp.
143. Park J.D., Kim D.H. Sulfamide derivatives as transition state analogue inhibitors for carboxypeptidase A. Bioorg. Med. Chem. 2004, 12:2349-2356.
144. Mock W.L., Tsay J.T. Sulfoximine and sulfodiimine transition state analog inhibitors for carboxypeptidase A. J. Am. Chem. Soc. 1989, 111:4467-4472.
145. Cathers B.E., Schloss J.V. The sulfonimidamide as a novel transition state analog for aspartic acid and metallo proteases. Bioorg. Med. Chem. Lett. 1999, 9:1527-1532.
146. Jin J.Y., Tian G.R., Kim D.H. Optically active 2-benzyl-3-methanesulfinylpropanoic acid: synthesis and evaluation as inhibitors for carboxypeptidase A. Bioorg. Med. Chem. 2003, 11:4377-4381.
147. Hill J.M., Lowe G. Synthesis of phosphorothioate esters of l-phenyl-lactic acid as transition-state inhibitors of carboxypeptidase A. J. Chem. Soc. Perkin Trans. 1995, 1:2001-2007.
148. Payne D.J., Bateson J.H., Tolson D., Gasson B., Khushi T., Ledent P., Frere J.M. Phosphonamidate analogues of dipeptides with carboxypeptidase A and beta-lactamase-inhibitory activity: elucidation of the mechanism of beta-lactamase inhibition by electrospray mass spectrometry. Biochem. J. 1996, 314(Pt 2):457-461.
149. Hanson J.E., Kaplan A.P., Bartlett P.A. Phosphonate analogues of carboxypeptidase A substrates are potent transition-state analogue inhibitors. Biochemistry 1989, 28:6294-6305.
150. Kam C.M., Nishino N., Powers J.C. Inhibition of thermolysin and carboxypeptidase A by phosphoramidates. Biochemistry 1979, 18:3032-3038.
151. Bartlett P.A., Marlowe C.K., Giannousis P.P., Hanson J.E. Phosphorus-containing peptide analogs as peptidase inhibitors. Cold Spring Harb. Symp. Quant. Biol. 1987, 52:83-90.
152. Kaplan A.P., Bartlett P.A. Synthesis and evaluation of an inhibitor of carboxypeptidase A with a Ki value in the femtomolar range. Biochemistry 1991, 30:8165-8170.
153. Fan H., Zhao Y.H., Byers L., Hammer R.P. Synthesis of phosphonopeptide and thiophosphonopeptide analogs as inhibitors of carboxypeptidase A. Peptides for New Millennium 2000, 91-93.
154. Kim H., Lipscomb W.N. Comparison of the structures of three carboxypeptidase A-phosphonate complexes determined by X-ray crystallography. Biochemistry 1991, 30:8171-8180.
155. M. Polla, Preparation of phosphoryl propanoic acid derivatives as inhibitors of carboxypeptidase U, PCT Int. Appl. (Astrazeneca AB, Swed.). WO 2003 027128, 29 pp.
156. B.O. Buckman, K. Emayan, I. Islam, K. May, J. Bryant, R. Mohan, C.L. West, S. Yuan, Preparation of phosphorus compounds as Plasma carboxypeptidase b inhibitors, PCT Int. Appl. (Schering Aktiengesellschaft, Germany). WO 2003 080631, 124 pp.
157. Wang Y.X., Zhao L., Nagashima M., Vincelette J., Sukovich D., Li W., Subramanyam B., Yuan S., Emayan K., Islam I., Hrvatin P., Bryant J., Light D.R., Vergona R., Morser J., Buckman B.O. A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization. Thromb. Haemost. 2007, 97:45-53.
158. Wang Y.X., da Cunha V., Vincelette J., Zhao L., Nagashima M., Kawai K., Yuan S., Emayan K., Islam I., Hosoya J., Sullivan M.E., Dole W.P., Morser J., Buckman B.O., Vergona R. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb. Haemost. 2007, 97:54-61.
159. Adler M., Buckman B., Bryant J., Chang Z., Chu K., Emayan K., Hrvatin P., Islam I., Morser J., Sukovich D., West C., Yuan S., Whitlow M. Structures of potent selective peptide mimetics bound to carboxypeptidase B. Acta Crystallogr. D. Biol. Crystallogr. 2008, 64:149-157.
160. K. Fushihara, C. Kikuchi, T. Matsushima, K. Kanemoto, E. Satoh, T. Yamamoto, K. Suzuki, Preparation of phosphonic acid derivatives having carboxypeptidase B inhibitory activity, PCT Int. Appl. (Meiji Seika Kaisha, Ltd., Japan). WO 2001 019836, 129 pp.
161. Suzuki K., Muto Y., Fushihara K., Kanemoto K., Iida H., Sato E., Kikuchi C., Matsushima T., Kato E., Nomoto M., Yoshioka S., Ishii H. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxypho sphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J. Pharmacol. Exp. Ther. 2004, 309:607-615.
162. Stander M.A., Steyn P.S., van Der Westhuizen F.H., Payne B.E. A kinetic study into the hydrolysis of the ochratoxins and analogues by carboxypeptidase A. Chem. Res. Toxicol. 2001, 14:302-304.
163. Pitout M.J., Nel W. The inhibitory effect of ochratoxin A on bovine carboxypeptidase A in vitro. Biochem. Pharmacol. 1969, 18:1837-1843.
164. Pitout M.J. A rapid spectrophotometric method for the assay of carboxypeptidase A. Biochem. Pharmacol. 1969, 18:1829-1836.
165. Tanaka T., Suda H., Naganawa H., Hamada M., Takeuchi T., Aoyagi T., Umezawa H. Production of (S)-alpha-benzylmalic acid, inhibitor of carboxypeptidase A by actinomycetes. J. Antibiot. (Tokyo) 1984, 37:682-684.
166. Ohuchi S., Okuyama A., Naganawa H., Aoyagi T., Umezawa H. Biosynthetic studies of arphamenines A and B. J. Antibiot. (Tokyo) 1984, 37:518-521.
167. Ogawa K., Naganawa H., Iinuma H., Aoyagi T., Umezawa H. The structure of histargin. J. Antibiot. (Tokyo) 1984, 37:984-987.
168. Umezawa H., Aoyagi T., Ogawa K., Iinuma H., Naganawa H., Hamada M., Takeuchi T. Histargin, a new inhibitor of carboxypeptidase B, produced by actinomycetes. J. Antibiot. (Tokyo) 1984, 37:1088-1090.
169. Moriguchi M., Umeda Y., Miyazaki K., Nakamura T., Ogawa K., Kojima F., Iinuma H., Aoyagi T. Synthesis of histargin and related compounds and their inhibition of enzymes. J. Antibiot. (Tokyo) 1988, 41:1823-1827.
170. Morita Y., Matsumura E., Okabe T., Shibata M., Sugiura M., Ohe T., Tsujibo H., Ishida N., Inamori Y. Biological activity of tropolone. Biol. Pharm. Bull. 2003, 26:1487-1490.
171. Sakagami Y., Tsujibo H., Hirai Y., Yamada T., Numata A., Inamori Y. Inhibitory activities of 2-pyridinecarboxylic acid analogs on phytogrowth and enzymes. Biol. Pharm. Bull. 1999, 22:1234-1236.
172. Kusano G., Takahira M., Shibano M., Kusano A., Okamoto Y., Tsujibo H., Numata A., Inamori Y. Studies on inhibitory activities of fukiic acid esters on germination, alpha-amylase and carboxypeptidase A. Biol. Pharm. Bull. 1998, 21:997-999.
173. Buchanan M.S., Carroll A.R., Edser A., Sykes M., Fechner G.A., Forster P.I., Guymer G.P., Quinn R.J. Lysianadioic acid, a carboxypeptidase B inhibitor from Lysiana subfalcata. Bioorg. Med. Chem. Lett. 2008, 18:1495-1497.
174. Inokuchi J., Okabe H., Yamauchi T., Nagamatsu A., Nonaka G., Nishioka I. Inhibitors of angiotensin-converting enzyme in crude drugs. II. Chem. Pharm. Bull. (Tokyo) 1985, 33:264-269.
175. Ibarz A., Garza S., Pagan J. Inhibitory effect of melanoidins from glucose-asparagine on carboxypeptidases activity. Eur. Food Res. Technol. 2008, 226:1277-1282.
176. Fonrose X., Ausseil F., Soleilhac E., Masson V., David B., Pouny I., Cintrat J.C., Rousseau B., Barette C., Massiot G., Lafanechere L. Parthenolide inhibits tubulin carboxypeptidase activity. Cancer Res. 2007, 67:3371-3378.
177. Cannell R.J., Kellam S.J., Owsianka A.M., Walker J.M. Results of a large scale screen of microalgae for the production of protease inhibitors. Planta Med. 1988, 54:10-14.
178. Araki T., Matsunaga S., Fusetani N. Koshikamide A2, a cytotoxic linear undecapeptide isolated from a marine sponge of Theonella sp. Biosci. Biotechnol. Biochem. 2005, 69:1318-1322.
179. Murakami M., Suzuki S., Itou Y., Kodani S., Ishida K. New anabaenopeptins, potent carboxypeptidase-A inhibitors from the cyanobacterium Aphanizomenon flos-aquae. J. Nat. Prod. 2000, 63:1280-1282.
180. P. Bjoerquist, M. Buchanan, M. Campitelli, A. Carroll, E. Hyde, J. Neve, M. Polla, R. Quinn, Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase U is beneficial, novel anabaenopeptin derivatives and intermediates thereof, PCT Int. Appl. (Astrazeneca AB, Swed.). WO 2005 039617, 73 pp.
181. Walther T., Renner S., Waldmann H., Arndt H.D. Synthesis and structure-activity correlation of a brunsvicamide-inspired cyclopeptide collection. ChemBioChem. 2009, 10:1153-1162.
182. Uchida M., Mogami O. Usefulness of breath test for evaluating pancreatic exocrine function using N-benzoyl-l-tyrosyl-1-13C-l-alanine sodium in non-invasive and conscious rats. Biol. Pharm. Bull. 2008, 31:785-788.
183. Huijghebaert S.M., Hofmann A.F. Pancreatic carboxypeptidase hydrolysis of bile acid-amino conjugates: selective resistance of glycine and taurine amidates. Gastroenterology 1986, 90:306-315.
184. Sebastian J.F., Liang G., Jabarin A., Thomas K., Wu H.B. Effect of enzyme-substrate interactions away from the reaction site on carboxypeptidase A catalysis. Bioorg. Chem. 1996, 24:290-303.
185. Martin M.T., Holmquist B., Riordan J.F. An angiotensin converting enzyme inhibitor is a tight-binding slow substrate of carboxypeptidase A. J. Inorg. Biochem. 1989, 36:39-50.
186. Stewart B.H., Reyner E.L., Tse E., Hayes R.N., Werness S., He J.X., Cody W.L., Doherty A.M. In vitro assessment of oral delivery for hexapeptide endothelin antagonists. Life Sci. 1996, 58:971-982.
187. Bundgaard H., Rasmussen G.J. Prodrugs of peptides. 11. Chemical and enzymatic hydrolysis kinetics of N-acyloxymethyl derivatives of a peptide-like bond. Pharm. Res. 1991, 8:1238-1242.
188. Fredholt K., Adrian C., Just L., Hoj Larsen D., Weng S., Moss B., Juel Friis G. Chemical and enzymatic stability as well as transport properties of a Leu-enkephalin analogue and ester prodrugs thereof. J. Control. Release. 2000, 63:261-273.
189. Dendorfer A., Wagemann M., Reissmann S., Dominiak P. Structural requirements for B2-agonists with improved degradation stability. Immunopharmacology 1999, 45:199-205.
190. Lazoura E., Campbell W., Yamaguchi Y., Kato K., Okada N., Okada H. Rational structure-based design of a novel carboxypeptidase R inhibitor. Chem. Biol. 2002, 9:1129-1139.
191. Shimomura Y., Kawamura T., Komura H., Campbell W., Okada N., Okada H. Modulation of procarboxypeptidase R (ProCPR) activation by complementary peptides to thrombomodulin. Microbiol. Immunol. 2003, 47:241-245.
192. Saghatelian A., Jessani N., Joseph A., Humphrey M., Cravatt B.F. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. USA 2004, 101:10000-10005.
193. Blum G., Mullins S.R., Keren K., Fonovic M., Jedeszko C., Rice M.J., Sloane B.F., Bogyo M. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat. Chem. Biol. 2005, 1:203-209.
194. Latt S.A., Auld D.S., Vallee B.L. Fluorescende determination of carboxypeptidase A activity based on electronic energy transfer. Anal. Biochem. 1972, 50:56-62.
195. Ng M., Auld D.S. A fluorescent oligopeptide energy transfer assay with broad applications for neutral proteases. Anal. Biochem. 1989, 183:50-56.
196. Sato E., Kanaoka Y. New fluorogenic substrates for microdetermination of carboxypeptidase A. Chem. Pharm. Bull. (Tokyo) 1988, 36:4494-4498.
197. Marme N., Knemeyer J.P., Wolfrum J., Sauer M. Highly sensitive protease assay using fluorescence quenching of peptide probes based on photoinduced electron transfer. Angew. Chem. Int. Ed. Engl. 2004, 43:3798-3801.
198. Hennig A., Florea M., Roth D., Enderle T., Nau W.M. Design of peptide substrates for nanosecond time-resolved fluorescence assays of proteases: 2,3-Diazabicyclo[2.2.2]oct-2-ene as a noninvasive fluorophore. Anal. Biochem. 2007, 360:255-265.
199. Wolff E.C., Schirmer E.W., Folk J.E. The kinetics of carboxypeptidase B activity. J. Biol. Chem. 1962, 237:3094-3099.
200. Lastovetskaya L.V., Vaganova T.I., Stepanov V.M. Determination of carboxypeptidase B activity on the chromophore substrate 2,4-dinitrophenyl-glycyl-glycyl-l-arginine. Chem. Nat. Comp. 1974, 10:857-858.
201. Pozdnev V.F., Varlamov O.L., Grigor'ian O.O., Gomazkov O.A. A new fluorogenic substrate of carboxypeptidase H-o-coumaroylphenylalanyl-alanyl-arginine. Bioorg. Khim. 1994, 20:406-412.
202. Fricker L.D., Devi L. Comparison of a spectrophotometric, a fluorometric, and a novel radiometric assay for carboxypeptidase E (EC 3.4.17.10) and other carboxypeptidase B-like enzymes. Anal. Biochem. 1990, 184:21-27.
203. Hendriks D., Scharpe S., van Sande M. Assay of carboxypeptidase N activity in serum by liquid-chromatographic determination of hippuric acid. Clin. Chem. 1985, 31:1936-1939.
204. Yajima R., Chikuma T., Kato T. Highly sensitive high-performance liquid chromatography-fluorimetric assay method for carboxypeptidase H activity. J. Chromatogr. B Biomed. Appl. 1995, 667:333-338.
205. Nivorozhkin A.L., Kolodziej A.F., Caravan P., Greenfield M.T., Lauffer R.B., McMurry T.J. Enzyme-Activated Gd(3+) Magnetic Resonance imaging contrast agents with a Prominent receptor-induced magnetization enhancement. Angew. Chem. Int. Ed. Engl. 2001, 40:2903-2906.
206. Ferrer M., Zuck P., Kolodin G., Mao S.S., Peltier R.R., Bailey C., Gardell S.J., Strulovici B., Inglese J. Miniaturizable homogenous time-resolved fluorescence assay for carboxypeptidase B activity. Anal. Biochem. 2003, 317:94-98.
207. Barrett J.T. An antibody to porcine carboxypeptidase B. Int. Arch. Allergy Appl. Immunol. 1965, 26:158-166.
208. Du M., Jin S., Guo Z.Q. A new competitive inhibitory monoclonal antibody to carboxypeptidase A (CPA). Chin. Chem. Lett. 1999, 10:121-122.
209. T. Hamada, S. Matsugi, T. Tanaka, Antibodies and immunoassay for detecting carboxypeptidase and procarboxypeptidase and for diagnosis of pancreas cancer, U.S. Pat. Appl. Publ., (Wako pure chemical Industries, Ltd, Japan). US 2006 073526, 54 pp.
210. Tani S., Akatsu H., Ishikawa Y., Okada N., Okada H. Preferential detection of pro-carboxypeptidase R by enzyme-linked immunosorbent assay. Microbiol. Immunol. 2003, 47:295-300.
211. Hillmayer K., Vancraenenbroeck R., De Maeyer M., Compernolle G., Declerck P.J., Gils A. Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor. J. Thromb. Haemost. 2008, 6:1892-1899.
212. Hergenrother P.J. Obtaining and screening compound collections: a user's guide and a call to chemists. Curr. Opin. Chem. Biol. 2006, 10:213-218.
213. R.S. Grennfield, S.S.A. An, L. Trifonov, J. Vaugeois, C. Slemon, Treatment, prevention and management of pain, fever, neoplasm, inflammation, and hemorrhagic diseases by compound for any aspirin-related activity other than TAFI inhibition, PCT Int. Appl. (American Diagnostica, Inc. USA; Quebepharma Recherche, Inc.). WO 2004 019882, 72 pp.
214. Fernandez D., Illa O., Aviles F.X., Branchadell V., Vendrell J., Ortuno R.M. Thioxophosphoranyl aryl- and heteroaryloxiranes as the representants of a new class of metallocarboxypeptidase inhibitors. Bioorg. Med. Chem. 2008, 16:4823-4828.
215. Fernandez D., Torres E., Aviles F.X., Ortuno R.M., Vendrell J. Cyclobutane-containing peptides: evaluation as novel metallocarboxypeptidase inhibitors and modelling of their mode of action. Bioorg. Med. Chem. 2009, 17:3824-3828.
216. Ortuno R.M., Moglioni A.G., Moltrasio G.Y. Cyclobutane biomolecules: synthetic approaches to amino acids, peptides and nucleosides. Curr. Org. Chem. 2005, 9:237-259.
217. Frackenpohl J., Arvidsson P.I., Schreiber J.V., Seebach D. The outstanding biological stability of beta- and gamma-peptides toward proteolytic enzymes: an in vitro investigation with fifteen peptidases. ChemBioChem. 2001, 2:445-455.
218. Fernandez D., Aviles F.X., Vendrell J. Aromatic organic compounds as scaffolds for metallocarboxypeptidase inhibitor design. Chem. Biol. Drug Des. 2009, 73:75-82.
219. Fernandez D., Aviles F.X., Vendrell J. A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur. J. Med. Chem. 2009, 44:3266-3271.
220. Weitz J.I., Hirsh J., Samama M.M. New antithrombotic drugs: American college of chest physicians evidence-based clinical practice guidelines (eighth ed.). Chest 2008, 133:234S-256S.
221. Bunnage M.E., Owen D.R. TAFIa inhibitors in the treatment of thrombosis. Curr. Opin. Drug Discov. Devel. 2008, 11:480-486.
222. Owen D.R., Bull D.J., Bunnage M.E., Glossop M.S., Maguire R.J., Strang R.S. Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg. Med. Chem. Lett. 2010, 20:92-96.
223. Rees D.C., Lipscomb W.N. Structure of the potato inhibitor complex of carboxypeptidase A at 2.5-A resolution. Proc. Natl. Acad. Sci. USA 1980, 77:4633-4637.
224. Rees D.C., Lewis M., Honzatko R.B., Lipscomb W.N., Hardman K.D. Zinc environment and cis peptide bonds in carboxypeptidase A at 1.75-A resolution. Proc. Natl. Acad. Sci. USA 1981, 78:3408-3412.
225. Rees D.C., Lipscomb W.N. Binding of ligands to the active site of carboxypeptidase A. Proc. Natl. Acad. Sci. USA 1981, 78:5455-5459.
226. Christianson D.W., Lipscomb W.N. Binding of a possible transition state analogue to the active site of carboxypeptidase A. Proc. Natl. Acad. Sci. USA 1985, 82:6840-6844.
227. Christianson D.W., Lipscomb W.N. X-ray crystallographic investigation of substrate binding to carboxypeptidase A at subzero temperature. Proc. Natl. Acad. Sci. USA 1986, 83:7568-7572.
228. Christianson D.W., David P.R., Lipscomb W.N. Mechanism of carboxypeptidase A: hydration of a ketonic substrate analogue. Proc. Natl. Acad. Sci. USA 1987, 84:1512-1515.
229. Shoham G., Christianson D.W., Oren D.A. Complex between carboxypeptidase A and a hydrated ketomethylene substrate analogue. Proc. Natl. Acad. Sci. USA 1988, 85:684-688.
230. Kim H., Lipscomb W.N. Crystal structure of the complex of carboxypeptidase A with a strongly bound phosphonate in a new crystalline form: comparison with structures of other complexes. Biochemistry 1990, 29:5546-5555.
231. Cappalonga A.M., Alexander R.S., Christianson D.W. Structural comparison of sulfodiimine and sulfonamide inhibitors in their complexes with zinc enzymes. J. Biol. Chem. 1992, 267:19192-19197.
232. Mangani S., Carloni P., Orioli P. X-ray diffraction study of the interaction between carboxypeptidase A and (S)-(+)-1-amino-2-phenylethyl phosphonic acid. Eur. J. Biochem. 1992, 203:173-177.
233. Mangani S., Carloni P., Orioli P. Crystal structure of the complex between carboxypeptidase A and the biproduct analog inhibitor l-benzylsuccinate at 2.0 A resolution. J. Mol. Biol. 1992, 223:573-578.
234. Ippolito J.A., Christianson D.W. The contribution of halogen atoms to protein-ligand interactions. Int. J. Biol. Macromol. 1992, 14:193-197.
235. Teplyakov A., Wilson K.S., Orioli P., Mangani S. High-resolution structure of the complex between carboxypeptidase A and l-phenyl lactate. Acta Crystallogr. D Biol. Crystallogr. 1993, 49:534-540.
236. van Aalten D.M., Chong C.R., Joshua-Tor L. Crystal structure of carboxypeptidase A complexed with d-cysteine at 1.75 A - inhibitor-induced conformational changes. Biochemistry 2000, 39:10082-10089.
237. Cho J.H., Kim D.H., Chung S.J., Ha N.C., Oh B.H., Yong Choi K. Insight into the stereochemistry in the inhibition of carboxypeptidase A with N-(hydroxyaminocarbonyl)phenylalanine: binding modes of an enantiomeric pair of the inhibitor to carboxypeptidase A. Bioorg. Med. Chem. 2002, 10:2015-2022.
238. Park J.D., Kim D.H., Kim S.J., Woo J.R., Ryu S.E. Sulfamide-based inhibitors for carboxypeptidase A. Novel type transition state analogue inhibitors for zinc proteases. J. Med. Chem. 2002, 45:5295-5302.
239. Pallares I., Fernandez D., Comellas-Bigler M., Fernandez-Recio J., Ventura S., Aviles F.X., Bode W., Vendrell J. Direct interaction between a human digestive protease and the mucoadhesive poly(acrylic acid). Acta Crystallogr. D. Biol. Crystallogr. 2008, D64:784-791.
240. Wang S.F., Tian G.R., Zhang W.Z., Jin J.Y. Characterization of alpha-nitromethyl ketone as a new zinc-binding group based on structural analysis of its complex with carboxypeptidase A. Bioorg. Med. Chem. Lett. 2009, 19:5009-5011. [Epub 2009 Jul 5012].
241. Wang S.F., Jin J.-Y., Zeng Z.H., Tian G.R. Optical 2-benzyl-5-hydroxy-4-oxopentanoic acids against carboxypeptidasenext term A: synthesis, kinetic evaluation and X-ray crystallographic study. Chin. Chem. Lett. 2010, 21:159-162.
242. Ryu S.-E., Choi H.-J., Kim D.H. Stereochemistry in inactivation of carboxypeptidase A. Structural analysis of the Inactivated carboxypeptidase A by an enantiomeric pair of 2-Benzyl-3,4-epoxybutanoic acids. J. Am. Chem. Soc. 1997, 119:38-41.
243. Yun M., Park C., Kim S., Nam D., Kim S.C., Kim D.H. The x-ray crystallographic study of covalently modified carboxypeptidase A by 2-benzyl-3,4-epoxybutanoic acid, a pseudomechanism-based inactivator. J. Am. Chem. Soc. 1992, 114:2281-2282.
244. Massova I., Martin P., de Mel S., Tanaka Y., Edwards B., Mobashery S. Crystallographic and computational insight on the mechanism of zinc-ion-dependent inactivation of carboxypeptidase A by 2-benzyl-3-iodopropanoate. J. Am. Chem. Soc. 1996, 118:12479-12480.
245. Chai J.J., He C., Li M., Tang L., Luo M. Crystal structure of carboxypeptidase A complexed with an inactivator in two crystal forms. Protein Eng. 1998, 11:841-845.
246. Fernandez D., Testero S., Vendrell J., Aviles F.X., Mobashery S. The X-ray structure of carboxypeptidase A inhibited by a thiirane mechanism-based inhibitor. Chem. Biol. Drug Des. 2010, 75:29-34.
247. Aloy P., Companys V., Vendrell J., Aviles F.X., Fricker L.D., Coll M., Gomis-Ruth F.X. The crystal structure of the inhibitor-complexed carboxypeptidase D domain II and the modeling of regulatory carboxypeptidases. J. Biol. Chem. 2001, 276:16177-16184.
248. Wallace A.C., Laskowski R.A., Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8:127-134.